Moors & Cabot’s Sanofi SNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $497K | Buy |
10,313
+2,146
| +26% | +$100K | 0.02% | 553 |
|
|
2025
Q4 | $396K | Buy |
8,167
+46
| +0.6% | +$2.28K | 0.02% | 601 |
|
|
2025
Q3 | $383K | Sell |
8,121
-186
| -2% | -$8.98K | 0.02% | 604 |
|
|
2025
Q2 | $401K | Buy |
8,307
+313
| +4% | +$16K | 0.02% | 566 |
|
|
2025
Q1 | $443K | Buy |
7,994
+514
| +7% | +$27.8K | 0.02% | 516 |
|
|
2024
Q4 | $361K | Sell |
7,480
-355
| -5% | -$18.1K | 0.02% | 602 |
|
|
2024
Q3 | $452K | Sell |
7,835
-453
| -5% | -$24.5K | 0.02% | 521 |
|
|
2024
Q2 | $402K | Buy |
8,288
+1,026
| +14% | +$49.5K | 0.02% | 540 |
|
|
2024
Q1 | $353K | Sell |
7,262
-248
| -3% | -$12.1K | 0.02% | 617 |
|
|
2023
Q4 | $373K | Buy |
7,510
+1,195
| +19% | +$58.4K | 0.02% | 555 |
|
|
2023
Q3 | $339K | Buy |
6,315
+843
| +15% | +$44.9K | 0.02% | 557 |
|
|
2023
Q2 | $295K | Sell |
5,472
-2,351
| -30% | -$127K | 0.02% | 623 |
|
|
2023
Q1 | $426K | Buy |
7,823
+792
| +11% | +$38.5K | 0.03% | 480 |
|
|
2022
Q4 | $341K | Buy |
7,031
+66
| +0.9% | +$2.9K | 0.02% | 536 |
|
|
2022
Q3 | $265K | Sell |
6,965
-109
| -2% | -$4.86K | 0.02% | 609 |
|
|
2022
Q2 | $354K | Sell |
7,074
-481
| -6% | -$25.5K | 0.03% | 508 |
|
|
2022
Q1 | $388K | Sell |
7,555
-14
| -0.2% | -$723 | 0.02% | 550 |
|
|
2021
Q4 | $379K | Buy |
7,569
+740
| +11% | +$36.6K | 0.02% | 550 |
|
|
2021
Q3 | $328K | Buy |
6,829
+701
| +11% | +$35.6K | 0.02% | 567 |
|
|
2021
Q2 | $323K | Buy |
6,128
+97
| +2% | +$5.06K | 0.02% | 545 |
|
|
2021
Q1 | $298K | Hold |
6,031
| – | – | 0.02% | 538 |
|
|
2020
Q4 | $293K | Sell |
6,031
-574
| -9% | -$28.3K | 0.02% | 531 |
|
|
2020
Q3 | $331K | Buy |
6,605
+172
| +3% | +$8.86K | 0.03% | 446 |
|
|
2020
Q2 | $329K | Buy |
6,433
+342
| +6% | +$16.6K | 0.04% | 427 |
|
|
2020
Q1 | $267K | Buy |
6,091
+226
| +4% | +$10.8K | 0.04% | 415 |
|
|
2019
Q4 | $296K | Sell |
5,865
-1,806
| -24% | -$84.6K | 0.03% | 468 |
|
|
2019
Q3 | $355K | Sell |
7,671
-86
| -1% | -$3.71K | 0.04% | 407 |
|
|
2019
Q2 | $336K | Buy |
7,757
+302
| +4% | +$12.8K | 0.04% | 381 |
|
|
2019
Q1 | $329K | Buy |
7,455
+2,200
| +42% | +$94.2K | 0.04% | 364 |
|
|
2018
Q4 | $227K | Sell |
5,255
-301
| -5% | -$13.3K | 0.04% | 427 |
|
|
2018
Q3 | $246K | Sell |
5,556
-2,115
| -28% | -$90.3K | 0.03% | 473 |
|
|
2018
Q2 | $307K | Buy |
7,671
+1,077
| +16% | +$42.4K | 0.04% | 411 |
|
|
2018
Q1 | $264K | Buy |
6,594
+97
| +1% | +$4.04K | 0.03% | 463 |
|
|
2017
Q4 | $281K | Sell |
6,497
-300
| -4% | -$13.8K | 0.04% | 433 |
|
|
2017
Q3 | $340K | Buy |
6,797
+303
| +5% | +$14.7K | 0.05% | 378 |
|
|
2017
Q2 | $311K | Buy |
6,494
+43
| +0.7% | +$2.06K | 0.05% | 387 |
|
|
2017
Q1 | $292K | Buy |
6,451
+611
| +10% | +$25.9K | 0.05% | 389 |
|
|
2016
Q4 | $235K | Sell |
5,840
-525
| -8% | -$20.7K | 0.04% | 442 |
|
|
2016
Q3 | $245K | Buy |
6,365
+850
| +15% | +$34.1K | 0.04% | 430 |
|
|
2016
Q2 | $231K | Sell |
5,515
-125
| -2% | -$5.13K | 0.04% | 428 |
|
|
2016
Q1 | $226K | Hold |
5,640
| – | – | 0.04% | 418 |
|
|
2015
Q4 | $240K | Sell |
5,640
-325
| -5% | -$15K | 0.04% | 411 |
|
|
2015
Q3 | $284K | Buy |
5,965
+100
| +2% | +$5.09K | 0.05% | 376 |
|
|
2015
Q2 | $291K | Sell |
5,865
-1,700
| -22% | -$86.2K | 0.05% | 391 |
|
|
2015
Q1 | $376K | Buy |
7,565
+725
| +11% | +$34.7K | 0.06% | 325 |
|
|
2014
Q4 | $314K | Buy |
6,840
+2,900
| +74% | +$141K | 0.05% | 371 |
|
|
2014
Q3 | $222K | Sell |
3,940
-200
| -5% | -$10.7K | 0.04% | 455 |
|
|
2014
Q2 | $221K | Buy |
+4,140
| New | +$220K | 0.04% | 457 |
|
Other funds holding SNY
MIP
Moors & Cabot's SNY Position: Q1 2026 in Review
Moors & Cabot increased its Sanofi (SNY) stake by 26% in Q1 2026, buying an estimated $100K and bringing the position to 10,313 shares worth $497K. The position accounts for 0.02% of the portfolio, ranked #553.
Moors & Cabot first reported a position in SNY in Q2 2014 and has held it in 48 quarters since. 738 funds tracked by Wall St. Rank hold SNY as of Q1 2026.
- Moors & Cabot held 10,313 shares of Sanofi worth $497K as of Q1 2026.
- Moors & Cabot bought 2,146 Sanofi shares in Q1 2026, an estimated $100K.
- Sanofi made up 0.02% of Moors & Cabot's portfolio in Q1 2026, its #553 holding.
- Moors & Cabot first reported a position in Sanofi in Q2 2014 and has held it in 48 quarters since.
- 738 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.
Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.